A US judge on Monday denied Novo Nordisk’s (NVO) bid to halt Eli Lilly’s (LLY) weight-loss drug advertisements, which the Danish pharmaceutical company alleged were false and misleading, in a market generating tens of billions of dollars in annual sales.
